NEPC, CRPC-NE and small cell carcinoma of the prostate (all aggressive forms of PCa) have been shown to exhibit divergent transcriptional programs with higher expression of NANOG, SOX2 and EZH2, which promote lineage plasticity and resistance to androgen-targeting therapies [59]. This evidence concerns the gene NANOG and posterior cortical atrophy.